Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2025-02-05 Sale |
2025-02-07 7:06 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
1,000 | $22.52 | $22,524 | 159,056 (Direct) |
View |
| 2025-01-27 Sale |
2025-01-29 7:21 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $21.59 | $70,178 | 160,056 (Direct) |
View |
| 2025-01-07 Sale |
2025-01-10 5:31 pm |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
28,367 | $24.18 | $685,868 | 381,880 (Indirect Direct) |
View |
| 2025-01-03 Sale |
2025-01-07 4:43 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
1,000 | $25.04 | $25,039 | 318,862 (Direct) |
View |
| 2024-12-27 Sale |
2024-12-31 5:18 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
4,250 | $22.23 | $94,474 | 329,512 (Direct) |
View |
| 2024-11-27 Sale |
2024-12-02 5:18 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
5,250 | $24.89 | $130,688 | 168,556 (Direct) |
View |
| 2024-10-28 Sale |
2024-10-30 6:04 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
6,250 | $28.56 | $178,485 | 173,806 (Direct) |
View |
| 2024-10-18 Sale |
2024-10-22 4:23 pm |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
716 | $30 | $21,483 | 343,311 (Indirect) |
View |
| 2024-10-18 Sale |
2024-10-22 4:22 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
847 | $30 | $25,413 | 1,015,188 (Indirect) |
View |
| 2024-10-18 Sale |
2024-10-22 4:21 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
924 | $30 | $27,723 | 1,002,892 (Indirect) |
View |
| 2024-10-18 Sale |
2024-10-22 4:19 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
814 | $30 | $24,422 | 180,056 (Direct) |
View |
| 2024-10-18 Sale |
2024-10-22 4:18 pm |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
1,570 | $30 | $47,104 | 188,245 (Indirect Direct) |
View |
| 2024-10-18 Sale |
2024-10-22 4:17 pm |
Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER |
816 | $30 | $24,482 | 266,268 (Direct) |
View |
| 2024-10-15 Sale |
2024-10-17 5:06 pm |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
1,270 | $27.67 | $35,143 | 189,815 (Indirect Direct) |
View |
| 2024-10-08 Sale |
2024-10-10 8:39 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
51,145 | $28.11 | $1,437,585 | 1,016,035 (Indirect) |
View |
| 2024-10-08 Sale |
2024-10-10 8:38 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
29,977 | $28.07 | $841,334 | 1,003,816 (Indirect) |
View |
| 2024-10-08 Sale |
2024-10-10 8:36 pm |
Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director |
10,420 | $28.17 | $293,557 | 104,091 (Direct) |
View |
| 2024-10-04 Sale |
2024-10-08 6:58 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
10,229 | $27.54 | $281,664 | 1,067,180 (Indirect) |
View |
| 2024-10-04 Sale |
2024-10-08 6:57 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
14,936 | $27.51 | $410,867 | 1,033,793 (Indirect) |
View |
| 2024-10-04 Sale |
2024-10-08 6:56 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
11,488 | $27.51 | $316,014 | 363,010 (Direct) |
View |
| 2024-10-04 Sale |
2024-10-08 6:54 pm |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
2,825 | $27.51 | $77,704 | 191,085 (Indirect Direct) |
View |
| 2024-10-01 Sale |
2024-10-03 6:47 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
527 | $27.54 | $14,512 | 1,077,409 (Indirect) |
View |
| 2024-10-01 Sale |
2024-10-03 6:45 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
526 | $27.54 | $14,485 | 1,048,729 (Indirect) |
View |
| 2024-10-01 Sale |
2024-10-03 6:44 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
521 | $27.54 | $14,347 | 192,358 (Direct) |
View |
| 2024-10-01 Sale |
2024-10-03 6:43 pm |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
518 | $27.54 | $14,264 | 193,910 (Indirect Direct) |
View |
| 2024-09-27 Sale |
2024-10-01 7:53 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
6,250 | $24.61 | $153,829 | 387,758 (Direct) |
View |
| 2024-09-16 Sale |
2024-09-18 4:17 pm |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
1,270 | $22.41 | $28,458 | 194,428 (Indirect Direct) |
View |
| 2024-08-29 Sale |
2024-09-03 5:43 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
12,000 | $22.49 | $269,841 | 1,077,936 (Indirect) |
View |
| 2024-08-27 Sale |
2024-08-29 6:36 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
4,250 | $22.54 | $95,782 | 199,129 (Direct) |
View |
| 2024-08-26 Sale |
2024-08-28 7:48 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
12,000 | $22.89 | $274,718 | 1,049,255 (Indirect) |
View |
| 2024-08-15 Sale |
2024-08-19 7:49 pm |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
1,270 | $23.25 | $29,526 | 195,698 (Indirect Direct) |
View |
| 2024-07-31 Sale |
2024-08-02 7:26 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
3,099 | $27.56 | $85,399 | 1,089,936 (Indirect) |
View |
| 2024-07-31 Sale |
2024-08-02 7:25 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
2,270 | $27.56 | $62,555 | 1,061,255 (Indirect) |
View |
| 2024-07-31 Sale |
2024-08-02 7:23 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
991 | $27.53 | $27,281 | 203,379 (Direct) |
View |
| 2024-07-31 Sale |
2024-08-02 7:22 pm |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
2,351 | $27.5 | $64,663 | 196,968 (Indirect Direct) |
View |
| 2024-07-29 Sale |
2024-07-31 7:33 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
12,000 | $26.7 | $320,378 | 1,093,035 (Indirect) |
View |
| 2024-07-29 Sale |
2024-07-31 7:31 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
5,250 | $26.68 | $140,052 | 204,370 (Direct) |
View |
| 2024-07-25 Sale |
2024-07-29 5:39 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
12,000 | $24.92 | $299,073 | 1,240,587 (Indirect) |
View |
| 2024-07-15 Sale |
2024-07-17 7:25 pm |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
1,270 | $24.8 | $31,497 | 199,319 (Indirect Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-02-06 Option Award |
2025-02-10 5:25 pm |
N/A 2035-02-06 |
Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER |
171,000 | $0 | 171,000 (Direct) |
View |
| 2025-02-05 Exercise |
2025-02-07 7:06 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
1,000 | $2.48 | 159,056 (Direct) |
View |
| 2025-02-05 Exercise |
2025-02-07 7:06 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
1,000 | $0 | 159,056 (Direct) |
View |
| 2025-01-27 Exercise |
2025-01-29 7:21 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $2.48 | 160,056 (Direct) |
View |
| 2025-01-27 Exercise |
2025-01-29 7:21 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $0 | 160,056 (Direct) |
View |
| 2025-01-07 Exercise |
2025-01-10 5:31 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
11,000 | $2.48 | 381,880 (Direct) |
View |
| 2025-01-07 Exercise |
2025-01-10 5:31 pm |
N/A 2030-06-16 |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
21,700 | $0 | 381,880 (Direct) |
View |
| 2025-01-07 Exercise |
2025-01-10 5:31 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
10,700 | $1.12 | 381,880 (Direct) |
View |
| 2024-12-13 Exercise |
2025-01-07 4:43 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
14,000 | $2.48 | 318,862 (Direct) |
View |
| 2024-12-13 Exercise |
2025-01-07 4:43 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
14,000 | $0 | 318,862 (Direct) |
View |
| 2024-12-27 Exercise |
2024-12-31 5:18 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
4,250 | $2.48 | 329,512 (Direct) |
View |
| 2024-12-27 Exercise |
2024-12-31 5:18 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
4,250 | $0 | 329,512 (Direct) |
View |
| 2024-11-27 Exercise |
2024-12-02 5:18 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
5,250 | $2.48 | 168,556 (Direct) |
View |
| 2024-11-27 Exercise |
2024-12-02 5:18 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
5,250 | $0 | 168,556 (Direct) |
View |
| 2024-10-28 Exercise |
2024-10-30 6:04 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
6,250 | $2.48 | 173,806 (Direct) |
View |
| 2024-10-28 Exercise |
2024-10-30 6:04 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
6,250 | $0 | 173,806 (Direct) |
View |
| 2024-10-18 Exercise |
2024-10-22 4:19 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
814 | $2.48 | 180,056 (Direct) |
View |
| 2024-10-18 Exercise |
2024-10-22 4:19 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
814 | $0 | 180,056 (Direct) |
View |
| 2024-10-18 Exercise |
2024-10-22 4:17 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER |
816 | $2.48 | 266,268 (Direct) |
View |
| 2024-10-18 Exercise |
2024-10-22 4:17 pm |
N/A 2031-06-17 |
Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER |
816 | $0 | 266,268 (Direct) |
View |
| 2024-10-08 Exercise |
2024-10-10 8:36 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director |
4,106 | $5.52 | 104,091 (Direct) |
View |
| 2024-10-08 Exercise |
2024-10-10 8:36 pm |
N/A 2029-05-16 |
Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director |
10,420 | $0 | 104,091 (Direct) |
View |
| 2024-10-08 Exercise |
2024-10-10 8:36 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director |
6,314 | $19.68 | 104,091 (Direct) |
View |
| 2024-10-04 Exercise |
2024-10-08 6:56 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
11,488 | $2.48 | 363,010 (Direct) |
View |
| 2024-10-04 Exercise |
2024-10-08 6:56 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
11,488 | $0 | 363,010 (Direct) |
View |
| 2024-10-01 Exercise |
2024-10-03 6:44 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
521 | $2.48 | 192,358 (Direct) |
View |
| 2024-10-01 Exercise |
2024-10-03 6:44 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
521 | $0 | 192,358 (Direct) |
View |
| 2024-09-27 Exercise |
2024-10-01 7:53 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
6,250 | $2.48 | 387,758 (Direct) |
View |
| 2024-09-27 Exercise |
2024-10-01 7:53 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
6,250 | $0 | 387,758 (Direct) |
View |
| 2024-08-27 Exercise |
2024-08-29 6:36 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
4,250 | $2.48 | 199,129 (Direct) |
View |
| 2024-08-27 Exercise |
2024-08-29 6:36 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
4,250 | $0 | 199,129 (Direct) |
View |
| 2024-07-31 Exercise |
2024-08-02 7:23 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
991 | $2.48 | 203,379 (Direct) |
View |
| 2024-07-31 Exercise |
2024-08-02 7:23 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
991 | $0 | 203,379 (Direct) |
View |
| 2024-07-29 Exercise |
2024-07-31 7:31 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
5,250 | $2.48 | 204,370 (Direct) |
View |
| 2024-07-29 Exercise |
2024-07-31 7:31 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
5,250 | $0 | 204,370 (Direct) |
View |